ASBMR 2018 REPORT －臨床系：骨粗鬆症の臨床－

A meeting Report on the 2018 annual meeting of ASBMR－Clinical practice of the osteoporosis－.

　2018年のASBMRは，新規骨粗鬆症治療薬の話題に乏しいものの，既存骨粗鬆症治療薬の骨質への効果やtreat-to-targetを意識した演題が多く報告された。しかし，プロバイオティクスやSARM（selective androgen receptor modulator：アンドロゲン受容体モジュレータ）など注目を集めた報告も散見された。

　In the 2018 ASBMR annual meeting, many important results were reported, showing the effects of anti-osteoporotic drugs already focusing on bone quality and the concept of "treat-to-target", although there were few big topics on novel drugs. However, some reports on new drugs, such as probiotics and SARM（selective androgen receptor modulator）, did draw attention.